Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Regadenoson. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114249785A details a hydrazine-free synthesis of regadenoson intermediates using cesium carbonate catalysis, offering safer manufacturing and high purity for pharmaceutical supply chains.
Patent CN104744540A reveals a safer atmospheric acylation route for Regadenoson. This report analyzes cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Novel patent CN105873938A details a high-yield regadenoson process avoiding genotoxic impurities ensuring supply chain stability and cost reduction in API manufacturing.
Novel alkaline crystallization method reduces Impurity A below 0.10% ensuring ICH Q3a compliance and supply chain stability for cardiac imaging agents globally.